Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology

European Journal of Pharmaceutical Sciences

Volumn 48, Issue 1-2, 2013, Pages 142-152

  George, Maya ^a   Ghosh, Indrajit ^b  

^a UNIVERSITY OF IOWA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Enthalpy; Media mill; Nanosuspension; Solubility; Stabilizer; Zeta potential

Indexed keywords

NAPROXEN; STABILIZING AGENT; SURFACTANT;

AQUEOUS SOLUTION; ARTICLE; CRITICAL QUALITY ATTRIBUTE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; ELECTROSTATIC PRECIPITATION; FEASIBILITY STUDY; HYDROPHOBICITY; PARTICLE SIZE; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SOLID STATE; STATIC ELECTRICITY; SUSPENSION; X RAY DIFFRACTION; ZETA POTENTIAL;

1-OCTANOL; DIOCTYL SULFOSUCCINIC ACID; DRUG COMPOUNDING; DRUG STABILITY; METHYLCELLULOSE; MOLECULAR WEIGHT; NANOPARTICLES; NAPROXEN; PHARMACEUTICAL PREPARATIONS; POLOXAMER; POLYETHYLENE GLYCOLS; SODIUM DODECYL SULFATE; SOLUBILITY; SURFACE-ACTIVE AGENTS; SUSPENSIONS; TRANSITION TEMPERATURE; VITAMIN E; WATER;

EID: 84870219955     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.10.004     Document Type: Article

References (39)

1. S. Branchu, P.-G. Rogueda, A.-P. Plumb, and W.-G. Cook A decision-support tool for the formulation of orally active, poorly soluble compounds Eur. J. Pharm. Sci. 32 2007 128 139
2. M.-L. Branham, T. Moyo, and T. Govender Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement Eur. J. Pharm. Biopharm. 80 1 2012 194 202
3. A.-M. Cerdeira, M. Mazzotti, and B. Gande Miconazole nanosuspensions: influence of formulation variables on particle size reduction and physical stability Int. J. Pharm. 396 2012 210 218
4. S. Chakraborty, D. Shukla, B. Mishra, and S. Singh Lipid-an emerging platform for oral delivery of drugs with poor bioavailability Eur. J. Pharm. Biopharm. 73 2009 1 15
5. J.-Y. Choi, J.-Y. Yoo, H.-S. Kwak, B.-U. Nam, and J. Lee Role of polymeric stabilizers for drug nanocrystal dispersions J. Curr. Appl. Phys. 5 2005 472 474
6. De Castro, C.-L.; Mitchell, B.-S.; 2002. In: Baraton, M.I. (Ed.), Synthesis, Functionalization and Surface Treatment of Nanoparticles. American Scientific Publishers, California, pp. 1-15.
7. B.-V. Eerdenbrugh, J. Vermant, J.-A. Martens, L. Froyen, J.-V. Humbeeck, P. Augustijns, and G.-V. Mooter A screening study of surface stabilization during the production of drug nanocrystals J. Pharm. Sci. 98 6 2009 2091 2103
8. I. Ghosh, S. Bose, R. Vippagunta, and F. Harmon Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth Int. J. Pharm. 409 2011 260 268
9. Ghosh, I.; Schenck, D.; Bose, S.; Ruegger, C.; 2012. Optimization of formulation and process parameters for the production of 3 nanosuspension by wet media milling technique: effect of Vitamin E TPGS 4 and nanocrystal particle size on oral absorption. Eur. J. Pharm. Sci. (Early online).
10. M.-J. Grau, O. Kayser, and R.-H. Müller Nanosuspensions of poorly soluble drugs - reproducibility of small scale production Int. J. Pharm. 196 2 2000 155 159
11. J. Hecq, M. Deleers, D. Fanara, H. Vranck, and K. Amighi Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine Int. J. Pharm. 299 2005 167 177
12. J. Hecq, M. Deleers, D. Fanara, H. Vranck, P. Boulanger, S.L. Lamer, and K. Amighi Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base Eur. J. Pharm. Biopharm. 64 2006 360 368
13. M. Juhnke, J. Berghausen, and C. Timpe Accelerated formulation development for milled active pharmaceutical ingredients using a screening approach Chem. Eng. Technol. 33 9 2010 1412 1418
14. J.-A.-H. Junghanns, and R.-H. Müller Nanocrystal technology, drug delivery and clinical applications Int. J. Nanomed. 3 3 2008 295 310
15. Y. Kawabataa, K. Wadab, M. Nakatanib, S. Yamadaa, and S. Onouea Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications Int. J. Pharm. 420 2011 1 10
16. K. Kawakami, N. Oda, K. Miyoshi, T. Funaki, and Y. Ida Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents Eur. J. Pharm. Sci. 28 2006 7 14
17. C.-M. Keck, and R.H. Müller Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation Eur. J. Pharm. Biopharm. 62 1 2006 3 16
18. F. Kesisoglou, S. Panmai, and Y. Wu Nanosizing-oral formulation development and biopharmaceutical evaluation Adv. Drug. Deliv. Rev. 59 2007 631 644
19. M.-K. Lee, and S. Kim Hydrophilic and hydrophobic amino acid copolymers for nano-communition of poorly soluble drugs Int. J. Pharm. 384 2010 173 180
20. J. Lee, J.-Y. Choi, and C.-H. Park Characteristics of polymers enabling nano-communiotion of water-insoluble drugs Int. J. Pharm. 355 2008 28 336
21. C.-A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharm. Toxicol. Met. 44 2000 235 249
22. P. Liu, X. Rong, J. Laru, B. van Veen, J. Kiesvaara, J. Hirvonen, T. Laaksonen, and L. Peltonen Nanosuspensions of poorly soluble drugs: preparation and development by wet milling Int. J. Pharm. 411 2011 215 222
23. E.-L. Merisko-Liversidge, and G.-G. Liversidge Drug nanoparticles: formulating poorly water-soluble compounds Toxicol. Pathol. 36 2008 43 48
24. E.-L. Merisko-Liversidge, and G.-G. Liversidge Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology Adv. Drug. Deliv. Rev. 63 2010 427 440
25. Y. Miyakoa, N. Khalefb, K. Matsuzakic, and R. Pinalb Solubility enhancement of hydrophobic compounds by cosolvents: role of solute hydrophobicity on the solubilization effect Int. J. Pharm. 393 2010 48 54
26. D. Mou, H. Chen, J. Wan, H. Xu, and X. Yang Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility Int. J. Pharm. 413 2011 237 244
27. R.-H. Müller, C. Jacobs, and O. Kayser Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future Adv. Drug. Deliv. Rev. 47 1 2001 3 19
28. T.-T. Niwa, S. Miura, and K. Danjo Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies-development of particle design method Int. J. Pharm. 405 2011 218 227
29. H. Owen, S. Graham, J.-O. Werling, and P.-W. Carter Anion effects on electrostatic charging of sterically stabilized, water insoluble drug particles Int. J. Pharm. 368 2009 154 159
30. V.-B. Patravale, A.-A. Date, and R.-M. Kulkarni Nanosuspensions: a promising drug delivery strategy J. Pharm. Pharmacol. 6 2004 827 840
31. L. Peltonen, and J. Hirvonen Pharmaceutical nanocrystals by media milling: critical process parameters, particle fracturing and stabilization methods J. Pharm. Pharmacol. 62 2010 1569 1579
32. P. Sharma, and S. Garg Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIVdrugs Adv. Drug. Deliv. Rev. 62 2010 491 502
33. P. Sharma, Z.-D. Zujovicb, G.-A. Bowmakerb, W.-A. Dennyc, and S. Garg Evaluation of a crystalline nanosuspension: polymorphism, process induced transformation and in vivo studies Int. J. Pharm. 408 2011 138 151
34. S. Stegemann, F. Leveiller, D. Franchic, H. Jong, and H. Lind́ene When poor solubility becomes an issue: from early stage to proof of concept Eur. J. Pharm. Sci. 31 2007 249 261
35. B. Van Eerdenbrugh, G.-V. Mooter, and P. Patrick Augustijns Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products Int. J. Pharm. 364 2008 64 75
36. S. Verma, Y. Lan, R. Gokhale, and D.-J. Burgess Quality by design approach to understand the process of nanosuspension preparation Int. J. Pharm. 377 2009 2185 2198
37. S. Verma, B.-D. Huey, and D.-J. Burgess Scanning probe microscopy method for nanosuspension stabilizer selection Langmuir 25 2009 12481 12487
38. S. Verma, S. Kumara, R. Gokhale, and D.-J. Burgess Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening Int. J. Pharm. 406 2011 145 152
39. L. Wu, J. Zhanga, and W. Watanabe Physical and chemical stability of drug nanoparticles Adv. Drug. Deliv. Rev. 63 6 2011 456 469